Pharmacokinetics, Immunogenicity, and Safety of a Modified YTE Antibody in Healthy Adults
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70107 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Maria Rosario und 17 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. Hauptthemen laut MEDLINE: Antibodies, Viral, Immunoglobulin G, SARS-CoV-2, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority.
Abstract (Originalsprache)
REGN17092, a fully human immunoglobulin (Ig) G1 antibody with M252Y/S254T/T256E (YTE) modification in the Fc portion, was assessed in a first‐in‐human study (ClinicalTrials.gov, NCT05923424). REGN17092 was designed to target the severe acute respiratory coronavirus 2 (SARS‐CoV‐2) S protein. However, due to the emergence of new SARS‐CoV‐2 variants, the program was discontinued. In this single‐center, randomized, placebo‐controlled, single‐ascending‐dose study, participants received a single IV dose of REGN17092 (300, 1200, or 2400 mg) or placebo, or a single SC dose of REGN17092 (300 or 1200) or placebo. Endpoints assessed included pharmacokinetics (PK), safety, and immunogenicity. Allometric scaling was used to predict the terminal half‐life of REGN17092 and to ensure adequate exposure multiples relative to the exposure at the NOAEL. Forty participants were included. Mean concentrations of REGN17092 in serum increased in a dose‐proportional manner and were consistent with linear PK for a single dose administered IV or SC. PK analysis of a single dose of REGN17092 administered IV or SC suggests that REGN17092 has a half‐life of 80–90 days and showed detectable penetration into nasal fluid. No anti‐drug antibody responses were noted. In this Phase 1 study, REGN17092 was tolerable with a long half‐life, highlighting the value of YTE modification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
- Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium.
Förderung
- U.S. Department of Health and Human Services
- Administration for Strategic Preparedness and Response
- Biomedical Advanced Research and Development Authority
Zitieren
APA
Rosario, M., de Hoon, J., Isa, F., Turner, K., Li, J., Kantrowitz, J., Ganguly, S., Fraser, S., He, Z. W., Yan, H., Ortiz, A. G., Faria, L., Heirman, I., Baum, A., Norton, T. D., Patel, Y., Casullo, V. M., & Davis, J. D. (2026). Pharmacokinetics, Immunogenicity, and Safety of a Modified YTE Antibody in Healthy Adults. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70107
Vancouver
Rosario M, de Hoon J, Isa F, Turner K, Li J, Kantrowitz J, et al. Pharmacokinetics, Immunogenicity, and Safety of a Modified YTE Antibody in Healthy Adults. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70107
BibTeX
@article{Rosario2026,
author = {Rosario, Maria and de Hoon, Jan and Isa, Flonza and Turner, Kenneth and Li, Jing and Kantrowitz, Joel and Ganguly, Samit and Fraser, Sasha and He, Zhongqing Will and Yan, Hong and Ortiz, Ana Gonzalez and Faria, Lori and Heirman, Ingeborg and Baum, Alina and Norton, Thomas D and Patel, Yogesh and Casullo, Veronica Mas and Davis, John D},
title = {Pharmacokinetics, Immunogenicity, and Safety of a Modified YTE Antibody in Healthy Adults},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70107}
}
EUVIMED